Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 76 for:    Long-chain fatty acids

Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03245749
Recruitment Status : Completed
First Posted : August 10, 2017
Last Update Posted : August 14, 2017
Sponsor:
Collaborators:
Food Standards Agency, United Kingdom
Ocean Nutrition
Information provided by (Responsible Party):
University of Southampton

Brief Summary:
The purpose of this study is to investigate the effect of habitual oily fish intake, sex, age, BMI, and APOE genotype on plasma long chain n-3 fatty acid composition.

Condition or disease
Plasma Omega-3 Status

Detailed Description:

The marine long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial to cardiovascular and cognitive health and the concentration of EPA and DHA present in blood and tissue lipids is positively correlated with these effects.

As a result, national and global authorities recommend regular consumption of oily fish in order to provide approximately 500 mg EPA+DHA per day in a healthy population. However, the associations between EPA and DHA intake and blood and tissue status, and therefore physiological benefits, are highly variable and the factors influencing this heterogeneity are not well understood.

This study aims to investigate the effect of habitual oily fish intake as well as sex, age, BMI, and Apolipoprotein E (APOE) genotype on LC n-3 PUFA status in plasma phosphatidylcholine, non-esterified fatty acids, cholesteryl esters and triacylglycerols in order to obtain greater knowledge of the determinants of LC n-3 PUFA status with the potential to develop more robust, and perhaps subgroup specific, recommendations for EPA and DHA intake.


Layout table for study information
Study Type : Observational
Actual Enrollment : 374 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition
Actual Study Start Date : June 2003
Actual Primary Completion Date : September 2005
Actual Study Completion Date : March 2006



Primary Outcome Measures :
  1. Plasma long chain n-3 polyunsaturated fatty acid concentrations [ Time Frame: Baseline ]
    Concentrations of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) in plasma phosphatidylcholine, non-esterified fatty acids, cholesteryl esters and triacylglycerols


Secondary Outcome Measures :
  1. APOE genotyping [ Time Frame: Baseline ]
    APOE genotype determined from blood sample

  2. Anthropometric measurements [ Time Frame: Baseline ]
    Height and weight to determine BMI


Biospecimen Retention:   Samples With DNA
Blood and plasma samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Individuals residing in Southampton, East Anglia, Glasgow and Newcastle
Criteria

Exclusion Criteria:

  • Diagnosed endocrine dysfunction including diabetes
  • Fasting glucose concentration > 6.5 mmol/L
  • Myocardial infarction in the previous 2 years
  • The use of medication that may interfere with lipid metabolism
  • Fasting total cholesterol of > 8.0 mmol/L
  • TG of > 3.0 mmol/L
  • Currently following a weight loss diet
  • Taking n-3 fatty acid supplements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03245749


Locations
Layout table for location information
United Kingdom
University of Glasgow
Glasgow, United Kingdom
Newcastle University
Newcastle upon Tyne, United Kingdom
Univeristy of East Anglia
Norwich, United Kingdom
University of Reading
Reading, United Kingdom
University of Southampton
Southampton, United Kingdom
Sponsors and Collaborators
University of Southampton
Food Standards Agency, United Kingdom
Ocean Nutrition
Investigators
Layout table for investigator information
Principal Investigator: Philip C Calder University of Southampton

Layout table for additonal information
Responsible Party: University of Southampton
ClinicalTrials.gov Identifier: NCT03245749     History of Changes
Other Study ID Numbers: RRD7/N02/A
First Posted: August 10, 2017    Key Record Dates
Last Update Posted: August 14, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Southampton:
omega-3 status
blood lipids
Eicosapentaenoic acid (EPA)
Docosahexaenoic acid (DHA)